PDCD1 and melanoma: Importantly, we present evidence that the intratumoral presence of Vδ1+ cells is a predictor of therapeutic response in patients with melanoma receiving anti-PD-1 and anti-PD-L1 therapy, particularly in the setting of low neoantigen loads where αβ T cell surveillance is most likely compromised.